These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab. Bughani U; Saha A; Kuriakose A; Nair R; Sadashivarao RB; Venkataraman R; Patel S; Deshchougule AT; S SK; Montero E; Pai HV; Palanivelu DV; Melarkode R; Nair P PLoS One; 2017; 12(7):e0180088. PubMed ID: 28672038 [TBL] [Abstract][Full Text] [Related]
5. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Loganathan S; Athalye SN; Joshi SR Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604 [TBL] [Abstract][Full Text] [Related]
6. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study. Gore V; Kshirsagar DP; Bhat SM; Khatib KI; Mansukhani B J Assoc Physicians India; 2021 Feb; 69(2):13-18. PubMed ID: 33527804 [TBL] [Abstract][Full Text] [Related]
7. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases. Filgueira LM; Cervantes JB; Lovelle OA; Herrera C; Figueredo C; Caballero JA; Sánchez N; Berrio J; Lorenzo G; Cepeda M; Ramos M; Saavedra D; Añe-Kouri AL; Mazorra Z; Leon K; Crombet T; Caballero A Immunotherapy; 2021 Mar; 13(4):289-295. PubMed ID: 33397150 [TBL] [Abstract][Full Text] [Related]
8. An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients. Saavedra D; Añé-Kourí AL; Sánchez N; Filgueira LM; Betancourt J; Herrera C; Manso L; Chávez E; Caballero A; Hidalgo C; Lorenzo G; Cepeda M; Valenzuela C; Ramos M; León K; Mazorra Z; Crombet T Immun Ageing; 2020 Nov; 17(1):34. PubMed ID: 33292350 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab. Hernández P; Moreno E; Aira LE; Rodríguez PC Curr Drug Targets; 2016; 17(6):666-77. PubMed ID: 26844560 [TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
11. Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center. Kumari P; Kumar A; Sinha C; Kumar A; Singh PK; Arun SK Indian J Crit Care Med; 2021 Apr; 25(4):467-469. PubMed ID: 34045817 [TBL] [Abstract][Full Text] [Related]
12. Itolizumab - a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis. Menon R; David BG Clin Cosmet Investig Dermatol; 2015; 8():215-22. PubMed ID: 25945063 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study. Krupashankar DS; Dogra S; Kura M; Saraswat A; Budamakuntla L; Sumathy TK; Shah R; Gopal MG; Narayana Rao T; Srinivas CR; Bhat R; Shetty N; Manmohan G; Sai Krishna K; Padmaja D; Pratap DV; Garg V; Gupta S; Pandey N; Khopkar U; Montero E; Ramakrishnan MS; Nair P; Ganapathi PC J Am Acad Dermatol; 2014 Sep; 71(3):484-92. PubMed ID: 24703722 [TBL] [Abstract][Full Text] [Related]
14. Rationale for treating primary Sjögren's syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab). Le Dantec C; Alonso R; Fali T; Montero E; Devauchelle V; Saraux A; Pers JO; Renaudineau Y Immunol Res; 2013 Jul; 56(2-3):341-7. PubMed ID: 23576060 [TBL] [Abstract][Full Text] [Related]
15. Itolizumab, a novel anti-CD6 monoclonal antibody: a safe and efficacious biologic agent for management of psoriasis. Dogra S; Uprety S; Suresh SH Expert Opin Biol Ther; 2017 Mar; 17(3):395-402. PubMed ID: 28064543 [TBL] [Abstract][Full Text] [Related]
17. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. Aira LE; López-Requena A; Fuentes D; Sánchez L; Pérez T; Urquiza A; Bautista H; Falcón L; Hernández P; Mazorra Z MAbs; 2014; 6(3):783-93. PubMed ID: 24594862 [TBL] [Abstract][Full Text] [Related]
18. A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis. Rodriguez PC; Torres-Moya R; Reyes G; Molinero C; Prada D; Lopez AM; Hernandez IM; Hernandez MV; Martinez JP; Hernandez X; Casaco A; Ramos M; Avila Y; Barrese Y; Montero E; Hernandez P Results Immunol; 2012; 2():204-11. PubMed ID: 24371585 [TBL] [Abstract][Full Text] [Related]
19. Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India. Budamakuntla L; Shree-Lakshmi HV; Bansal A; Venkatarayaraju SK Psoriasis (Auckl); 2019; 9():19-27. PubMed ID: 31119094 [TBL] [Abstract][Full Text] [Related]
20. Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era. Thangaraju P; Venkatesan N; Thangaraju E; Venkatesan S SN Compr Clin Med; 2020; 2(11):2131-2136. PubMed ID: 33015549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]